Based on the key indicators related to PTC Therapeutics' liquidity, profitability, solvency, and operating efficiency, PTC Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, PTC Therapeutics' Total Liabilities is comparatively stable compared to the past year. Property Plant Equipment is likely to gain to about 87.7 M in 2025, whereas Short Term Investments are likely to drop slightly above 281.6 M in 2025. Key indicators impacting PTC Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for PTC Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor PTC Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in PTC Therapeutics.
Please note, the imprecision that can be found in PTC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of PTC Therapeutics. Check PTC Therapeutics' Beneish M Score to see the likelihood of PTC Therapeutics' management manipulating its earnings.
PTC Therapeutics Stock Summary
PTC Therapeutics competes with Krystal Biotech, Sarepta Therapeutics, Iovance Biotherapeutics, Madrigal Pharmaceuticals, and Blueprint Medicines. PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Ptc Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what PTC Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining PTC Therapeutics's current stock value. Our valuation model uses many indicators to compare PTC Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PTC Therapeutics competition to find correlations between indicators driving PTC Therapeutics's intrinsic value. More Info.
PTC Therapeutics is rated below average in return on equity category among its peers. It is regarded third in return on asset category among its peers . At this time, PTC Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value PTC Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
PTC Therapeutics Systematic Risk
PTC Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PTC Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on PTC Therapeutics correlated with the market. If Beta is less than 0 PTC Therapeutics generally moves in the opposite direction as compared to the market. If PTC Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PTC Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PTC Therapeutics is generally in the same direction as the market. If Beta > 1 PTC Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
PTC Therapeutics Thematic Clasifications
PTC Therapeutics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Today, most investors in PTC Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PTC Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of PTC Therapeutics growth as a starting point in their analysis.
PTC Therapeutics February 1, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PTC Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PTC Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of PTC Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing PTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PTC Therapeutics's daily price indicators and compare them against related drivers.
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.